Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 2 of 530 resources

Videos

Evolution of Tumor-specific T Cell Production

This video features Juan Vera, Chief Development Officer at Marker Therapeutics, discussing how Marker used G-Rex® Bioreactors and the Lovo Cell Processing System to evolve and simplify manufacturing of its multiple tumor-associated antigen (MultiTAA) T cell therapy in anticipation of commercialization. This ScaleReady-sponsored seminar originally aired at the CAR-TCR Virtual 2021 Conference (Hanson Wade) on September 1st, 2021.

Scientific Posters T-Cells

Determining Optimal Seeding Density for Human T Cell Expansion in G-Rex®

Seeding human T cells at 0.5 x 10^6 cells/cm2 instead of 1.0 x 10^6 cells/cm2 in a G-Rex®6M well plate roughly doubled fold expansion, 70-fold against 36-fold at day 8, while final yields stayed similar at 3.7 x 10^8 and 3.8 x 10^8 viable cells. Purified CD3+ cells from three donors were activated with Cloudz CD3/CD28 microspheres, expanded undisturbed in ExCellerate medium with interleukin-7 at 10 ng/mL and interleukin-15 at 5 ng/mL, and sampled to day 10. Viability stayed above 85 per cent and dipped by day 10 as lactate plateaued after day 7. At the lower density CD4 cells expanded 33-fold to 1 x 10^8 and CD8 cells 118-fold to 2.5 x 10^8.